{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:37:40Z","timestamp":1790620660386,"version":"4.1.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["schres-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.schres.2013.06.038","type":"journal-article","created":{"date-parts":[[2013,7,18]],"date-time":"2013-07-18T09:15:29Z","timestamp":1374138929000},"page":"88-95","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"title":["Adenosine hypothesis in schizophrenia and bipolar disorder: A systematic review and meta-analysis of randomized controlled trial of adjuvant purinergic modulators"],"prefix":"10.1016","volume":"149","author":[{"given":"Tomoya","family":"Hirota","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Kishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5 Pt 1","key":"10.1016\/j.schres.2013.06.038_bb0005","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1399-5618.2006.00363.x","article-title":"Allopurinol as an adjunct to lithium and haloperidol for treatment of patients with acute mania: a double-blind, randomized, placebo-controlled trial","volume":"8","author":"Akhondzadeh","year":"2006","journal-title":"Bipolar Disord."},{"issue":"2","key":"10.1016\/j.schres.2013.06.038_bb0010","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.pnpbp.2004.11.008","article-title":"Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial","volume":"29","author":"Akhondzadeh","year":"2005","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2013.06.038_bb0015","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1046\/j.1365-2710.2000.00273.x","article-title":"Dipyridamole in the treatment of schizophrenia: adenosine\u2013dopamine receptor interactions","volume":"25","author":"Akhondzadeh","year":"2000","journal-title":"J. Clin. Pharm. Ther."},{"issue":"1","key":"10.1016\/j.schres.2013.06.038_bb0020","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.coph.2007.09.002","article-title":"Adenosine as a neuromodulator in neurological diseases","volume":"8","author":"Boison","year":"2008","journal-title":"Curr. Opin. Pharmacol."},{"issue":"3","key":"10.1016\/j.schres.2013.06.038_bb0025","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/j.neuropharm.2011.01.048","article-title":"Adenosine hypothesis of schizophrenia\u2014opportunities for pharmacotherapy","volume":"62","author":"Boison","year":"2012","journal-title":"Neuropharmacology"},{"issue":"2","key":"10.1016\/j.schres.2013.06.038_bb0030","doi-asserted-by":"crossref","first-page":"213","DOI":"10.4088\/JCP.v66n0209","article-title":"A clinical trial of adjuvant allopurinol therapy for moderately refractory schizophrenia","volume":"66","author":"Brunstein","year":"2005","journal-title":"J. Clin. Psychiatry"},{"issue":"12","key":"10.1016\/j.schres.2013.06.038_bb0035","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1345\/aph.1H222","article-title":"Allopurinol as adjuvant therapy in poorly responsive or treatment refractory schizophrenia","volume":"40","author":"Buie","year":"2006","journal-title":"Ann. Pharmacother."},{"issue":"2","key":"10.1016\/j.schres.2013.06.038_bb0040","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1152\/physrev.00043.2006","article-title":"Physiology and pathophysiology of purinergic neurotransmission","volume":"87","author":"Burnstock","year":"2007","journal-title":"Physiol. Rev."},{"issue":"2\u20133","key":"10.1016\/j.schres.2013.06.038_bb0045","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.schres.2005.02.013","article-title":"Manual for the Extrapyramidal Symptom Rating Scale (ESRS)","volume":"76","author":"Chouinard","year":"2005","journal-title":"Schizophr. Res."},{"issue":"2\u20133","key":"10.1016\/j.schres.2013.06.038_bb0050","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.psychres.2009.07.012","article-title":"Increased risk of gout among patients with bipolar disorder: a nationwide population-based study","volume":"180","author":"Chung","year":"2010","journal-title":"Psychiatry Res."},{"issue":"8","key":"10.1016\/j.schres.2013.06.038_bb0055","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/j.1399-5618.2009.00760.x","article-title":"The role of dopamine in bipolar disorder","volume":"11","author":"Cousins","year":"2009","journal-title":"Bipolar Disord."},{"issue":"4\u20136","key":"10.1016\/j.schres.2013.06.038_bb0060","first-page":"365","article-title":"Glutamate and schizophrenia: beyond the dopamine hypothesis","volume":"26","author":"Coyle","year":"2006","journal-title":"Cell. Mol. Neurobiol."},{"issue":"3","key":"10.1016\/j.schres.2013.06.038_bb0065","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1021\/jm00345a001","article-title":"Adenosine receptors: targets for future drugs","volume":"25","author":"Daly","year":"1982","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.schres.2013.06.038_bb0070","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control. Clin. Trials"},{"issue":"1\u20133","key":"10.1016\/j.schres.2013.06.038_bb0075","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.schres.2008.12.028","article-title":"A double-blind trial of adjunctive allopurinol for schizophrenia","volume":"109","author":"Dickerson","year":"2009","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2013.06.038_bb0080","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1146\/annurev.neuro.24.1.31","article-title":"The role and regulation of adenosine in the central nervous system","volume":"24","author":"Dunwiddie","year":"2001","journal-title":"Annu. Rev. Neurosci."},{"issue":"2","key":"10.1016\/j.schres.2013.06.038_bb0085","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1399-5618.2012.01001.x","article-title":"Allopurinol augmentation in the outpatient treatment of bipolar mania: a pilot study","volume":"14","author":"Fan","year":"2012","journal-title":"Bipolar Disord."},{"issue":"2","key":"10.1016\/j.schres.2013.06.038_bb0090","first-page":"CD002853","article-title":"Propentofylline for dementia","author":"Frampton","year":"2003","journal-title":"Cochrane Database Syst. Rev."},{"issue":"9","key":"10.1016\/j.schres.2013.06.038_bb0095","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1176\/appi.ajp.158.9.1367","article-title":"The emerging role of glutamate in the pathophysiology and treatment of schizophrenia","volume":"158","author":"Goff","year":"2001","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2013.06.038_bb0100","series-title":"Manual for the ECDEU Assessment Battery","author":"Guy","year":"1970"},{"issue":"7414","key":"10.1016\/j.schres.2013.06.038_bb0105","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.schres.2013.06.038_bb0110","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nrd1983","article-title":"Adenosine receptors as therapeutic targets","volume":"5","author":"Jacobson","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.schres.2013.06.038_bb0115","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.jad.2011.10.045","article-title":"Efficacy and safety of olanzapine in the treatment of Japanese patients with bipolar I disorder in a current manic or mixed episode: a randomized, double-blind, placebo- and haloperidol-controlled study","volume":"136","author":"Katagiri","year":"2012","journal-title":"J. Affect. Disord."},{"issue":"Supplement (7)","key":"10.1016\/j.schres.2013.06.038_bb0120","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1192\/S0007125000291514","article-title":"The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation","author":"Kay","year":"1989","journal-title":"Br. J. Psychiatry"},{"issue":"1\u20133","key":"10.1016\/j.schres.2013.06.038_bb0125","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jad.2008.05.014","article-title":"Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- and lithium-controlled study","volume":"112","author":"Keck","year":"2009","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.schres.2013.06.038_bb0130","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1192\/bjp.187.3.229","article-title":"Risperidone in the treatment of acute mania: double-blind, placebo-controlled study","volume":"187","author":"Khanna","year":"2005","journal-title":"Br. J. Psychiatry J. Ment. Sci."},{"key":"10.1016\/j.schres.2013.06.038_bb0135","article-title":"NMDA receptor antagonists interventions in schizophrenia: meta-analysis of randomized, placebo-controlled trials","author":"Kishi","year":"2013","journal-title":"J. Psychiatr. Res."},{"issue":"Suppl. 3","key":"10.1016\/j.schres.2013.06.038_bb0140","first-page":"S166","article-title":"Clinical trials of propentofylline in vascular dementia. European\/Canadian Propentofylline Study Group","volume":"13","author":"Kittner","year":"1999","journal-title":"Alzheimer Dis. Assoc. Disord."},{"issue":"4","key":"10.1016\/j.schres.2013.06.038_bb0145","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/00004850-200107000-00008","article-title":"Allopurinol augmentation for poorly responsive schizophrenia","volume":"16","author":"Lara","year":"2001","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.schres.2013.06.038_bb0150","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.pnpbp.2006.02.002","article-title":"Involvement of adenosine in the neurobiology of schizophrenia and its therapeutic implications","volume":"30","author":"Lara","year":"2006","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"8","key":"10.1016\/j.schres.2013.06.038_bb0155","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1056\/NEJM199708213370806","article-title":"Discrepancies between meta-analyses and subsequent large randomized, controlled trials","volume":"337","author":"LeLorier","year":"1997","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.schres.2013.06.038_bb0160","first-page":"CD003834","article-title":"Lithium for schizophrenia","author":"Leucht","year":"2007","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.schres.2013.06.038_bb0165","article-title":"Rapid resolution of psychotic symptoms in a patient with schizophrenia using allopurinol as an adjuvant","volume":"1\u201310","author":"Linden","year":"2013","journal-title":"Clin. Schizophr. Relat. Psychoses"},{"issue":"5","key":"10.1016\/j.schres.2013.06.038_bb0170","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1097\/JCP.0b013e318268391d","article-title":"Purinergic system in the treatment of bipolar disorder: uric acid levels as a screening test in mania","volume":"32","author":"Machado-Vieira","year":"2012","journal-title":"J. Clin. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.schres.2013.06.038_bb0175","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1054\/mehy.2001.1543","article-title":"Purinergic dysfunction in mania: an integrative model","volume":"58","author":"Machado-Vieira","year":"2002","journal-title":"Med. Hypotheses"},{"issue":"8","key":"10.1016\/j.schres.2013.06.038_bb0180","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.4088\/JCP.v69n0806","article-title":"A double-blind, randomized, placebo-controlled 4-week study on the efficacy and safety of the purinergic agents allopurinol and dipyridamole adjunctive to lithium in acute bipolar mania","volume":"69","author":"Machado-Vieira","year":"2008","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2013.06.038_bb0185","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.schres.2013.06.038_bb0190","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1124\/pr.58.1.6","article-title":"Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol","volume":"58","author":"Pacher","year":"2006","journal-title":"Pharmacol. Rev."},{"issue":"1","key":"10.1016\/j.schres.2013.06.038_bb0195","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/sj.bjp.0704061","article-title":"Neuromodulatory effect of propentofylline on rat brain under acute and long-term hypoperfusion","volume":"133","author":"Plaschke","year":"2001","journal-title":"Br. J. Pharmacol."},{"issue":"2\u20133","key":"10.1016\/j.schres.2013.06.038_bb0200","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0014-2999(97)01122-9","article-title":"Adenosine A1 and A2 receptor agonists significantly prevent the electroencephalographic effects induced by MK-801 in rats","volume":"333","author":"Popoli","year":"1997","journal-title":"Eur. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.schres.2013.06.038_bb0205","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.pnpbp.2007.11.021","article-title":"A placebo controlled study of the propentofylline added to risperidone in chronic schizophrenia","volume":"32","author":"Salimi","year":"2008","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2013.06.038_bb0210","first-page":"CD004028","article-title":"Valproate for schizophrenia","author":"Schwarz","year":"2008","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.schres.2013.06.038_bb0215","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatr. Scand. Suppl."},{"issue":"10","key":"10.1016\/j.schres.2013.06.038_bb0220","doi-asserted-by":"crossref","first-page":"859","DOI":"10.2165\/11586650-000000000-00000","article-title":"Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia","volume":"25","author":"Singh","year":"2011","journal-title":"CNS drugs"},{"issue":"5","key":"10.1016\/j.schres.2013.06.038_bb0225","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1093\/schbul\/sbr004","article-title":"Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review","volume":"38","author":"Sommer","year":"2012","journal-title":"Schizophr. Bull."},{"issue":"3","key":"10.1016\/j.schres.2013.06.038_bb0230","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/j.1399-5618.2010.00815.x","article-title":"A randomized, placebo- and active-controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder","volume":"12","author":"Vieta","year":"2010","journal-title":"Bipolar Disord."},{"issue":"1","key":"10.1016\/j.schres.2013.06.038_bb0235","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.schres.2012.02.014","article-title":"A randomized controlled trial of allopurinol vs. placebo added on to antipsychotics in patients with schizophrenia or schizoaffective disorder","volume":"138","author":"Weiser","year":"2012","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.schres.2013.06.038_bb0240","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00213-011-2315-3","article-title":"Dipyridamole monotherapy in schizophrenia: pilot of a novel treatment approach by modulation of purinergic signaling","volume":"218","author":"Wonodi","year":"2011","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.schres.2013.06.038_bb0245","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1192\/bjp.133.5.429","article-title":"A rating scale for mania: reliability, validity and sensitivity","volume":"133","author":"Young","year":"1978","journal-title":"Br. J. Psychiatry J. Ment. Sci."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996413003381?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996413003381?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,18]],"date-time":"2019-07-18T18:28:56Z","timestamp":1563474536000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996413003381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":49,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S0920996413003381"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2013.06.038","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adenosine hypothesis in schizophrenia and bipolar disorder: A systematic review and meta-analysis of randomized controlled trial of adjuvant purinergic modulators","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2013.06.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}